VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Willing and able to provide written informed       │ Willing and able to provide written informed       │     100 │
│ consent and accept study procedures and time       │ consent and accept study procedures and time       │         │
│ schedule                                           │ schedule                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients suffering from chronic heart failure (the │ Patients suffering from chronic heart failure (the │     100 │
│ heart failure diagnosis must have been made or     │ heart failure diagnosis must have been made or     │         │
│ confirmed by a cardiologist and/or hospital        │ confirmed by a cardiologist and/or hospital        │         │
│ physician at any time in the patient's medical     │ physician at any time in the patient's medical     │         │
│ history)                                           │ history)                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of investigational drugs either within 5 half- │ Use of investigational drugs either within 5 half- │     100 │
│ lives of enrollment, or within 30 days, or until   │ lives of enrollment, or within 30 days, or until   │         │
│ the expected pharmacodynamic effect has returned   │ the expected pharmacodynamic effect has returned   │         │
│ to baseline, whichever is longer                   │ to baseline, whichever is longer                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major surgery in the last 3 months prior to        │ Major surgery in the last 3 months prior to        │     100 │
│ baseline or planned major surgery or cardiac       │ baseline or planned major surgery or cardiac       │         │
│ intervention during the study                      │ intervention during the study                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cancer or other significant co-morbidities         │ Cancer or other significant co-morbidities         │     100 │
│ implying that the patient's condition is unstable  │ implying that the patient's condition is unstable  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Comorbidities that can be associated with elevated │ Comorbidities that can be associated with elevated │     100 │
│ natriuretic peptide (NP) levels: renal             │ natriuretic peptide (NP) levels: renal             │         │
│ insufficiency, (eGFR \< 25 ml/min/1.73 m²          │ insufficiency, (eGFR < 25 ml/min/1.73 m²           │         │
│ calculated according to MDRD formula), recent      │ calculated according to MDRD formula), recent      │         │
│ (less than 3 months) cerebral trauma or recent     │ (less than 3 months) cerebral trauma or recent     │         │
│ (less than 3 months) cerebrovascular incident,     │ (less than 3 months) cerebrovascular incident,     │         │
│ novel diagnosis or acute exacerbation of COPD      │ novel diagnosis or acute exacerbation of COPD      │         │
│ within the last 3 months                           │ within the last 3 months                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are primarily managed and regularly   │ Patients who are primarily managed and regularly   │     100 │
│ followed-up by a cardiologist for their HF         │ followed-up by a cardiologist for their HF         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Highly frail patients whose estimated lifespan due │ Highly frail patients whose estimated lifespan due │     100 │
│ to comorbidities by the judgement of the           │ to comorbidities by the judgement of the           │         │
│ investigator is less than 6 months                 │ investigator is less than 6 months                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age ≥ 18 years                                     │ Age = 18 years                                     │      93 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with reduced ejection fraction (≤ 40%) as │ Patients with reduced ejection fraction (= 40%) as │      99 │
│ confirmed at any time point in the patient's       │ confirmed at any time point in the patient's       │         │
│ medical history                                    │ medical history                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria   │   Score │
╞═══════════════════════════════════╪═════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Age = 18 years  │      47 │
╘═══════════════════════════════════╧═════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 94.45454545454545
OverAll Ratio: 96.72727272727272
